There is evidence that in rheumatoid arthritis (RA), alternate daily adrenal corticosteroid (steroid) dosage provides a more favourable therapeutic-totoxic ratio than does the same total dosage given as a daily regimen. There is agreement that, in contrast to daily dosage, alternate daily steroids tend not to suppress hypothalamo-pituitary-adrenal (HPA) axis responsiveness,l and other adverse effects appear to be lessened by alternate daily administration.-4
There is evidence that in rheumatoid arthritis (RA), alternate daily adrenal corticosteroid (steroid) dosage provides a more favourable therapeutic-totoxic ratio than does the same total dosage given as a daily regimen. There is agreement that, in contrast to daily dosage, alternate daily steroids tend not to suppress hypothalamo-pituitary-adrenal (HPA) axis responsiveness,l and other adverse effects appear to be lessened by alternate daily administration. -4 The popularity of steroids for treating the joint manifestations of RA is decreasing. Nevertheless it seems likely that some patients will continue to be started on this form of therapy. For Ten of the 24 patients successfully converted to alternate daily steroids over a mean period of 12 weeks. Eleven failed to convert and returned to their previous daily dosage. Three were withdrawn from the study: 2 moved from our area; 1 defaulted before conversion was attempted.
During the first few weeks of attempted conversion all patients experienced increasing stiffness, most prominent on the 'off' or reducing day. In those who failed to convert this stiffness lasted for progressively longer periods, and despite added supplementary medication this became a problem also on the 'on' day.
Those who successfully converted to alternate daily steroids were finally stabilised on the same total dose of prednisolone. By clinical and laboratory criteria their disease activity was the same as when they had been on daily steroids, and their analgesic and NSAID regimen was approximately the same.
There was no correlation between the ability to convert and the dose or duration of steroid treatment, nor with the severity or duration of disease (Table 2 ). However, of those patients investigated by the tetracosactrin stimulation test all 9 'converters' gave a normal response, while 6 of 10 who failed to respond gave abnormal (inadequate) responses (Table 3) .
During the 24 weeks of the study no significant change occurred in the various clinical and laboratory features which were followed as measures of undesirable steroid 'side effects'. Serum cortisol response to tetracosactrin Normal Abnormal Converters (n = 9) 9 0 Failed conversion (n = 10) 4 6 Fisher's exact test p < 0 .05.
Discussion
This study was 
